RESUMO
Radiation of benign disease is controversial. The approach of 55 South African radiation oncologists to 14 benign conditions was obtained and compared to available American data. In general, the approach was conservative except in cases of keloids. The South African and American approaches are remarkably similar (except with regard to ankylosing spondylitis). Private radiation oncologists are less conservative than their hospital counterparts. Randomised trials are needed firmly to establish efficacy and long-term side-effects.
Assuntos
Radioterapia/estatística & dados numéricos , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Radioterapia/efeitos adversos , África do Sul , Inquéritos e QuestionáriosRESUMO
Tongue biopsies of 30 diagnosed cases of multiple myeloma were examined light and electron microscopically and amyloid deposits were identified in 8 patients. Immunochemical typing of amyloid in kappa and lambda subtypes was performed successfully although positive staining of tissue-associated immunoglobulin light chains made reliable identification of amyloid with this technique difficult. Cells of macrophage lineage appear to play a central role in light chain-associated amyloidogenesis. Our findings do not agree with the reported higher amyloidogenic potential of lambda light chains and we were unable to show a positive correlation between the percentage plasma cells in bone marrow aspirates or the presence of urinary light chains and myeloma-associated amyloidosis.
Assuntos
Amiloidose/etiologia , Mieloma Múltiplo/complicações , Doenças da Língua/etiologia , Adulto , Idoso , Amiloide , Amiloidose/patologia , Estudos de Coortes , Vermelho Congo , Feminino , Humanos , Técnicas Imunoenzimáticas , Cadeias kappa de Imunoglobulina/análise , Cadeias lambda de Imunoglobulina/análise , Masculino , Pessoa de Meia-Idade , Doenças da Língua/patologiaRESUMO
The effect of age as a prognostic factor in recurrent breast cancer was studied in 1,168 patients treated on Eastern Cooperative Oncology Group (ECOG) protocols. Survival was significantly shorter in patients less than 35 years of age (P = .03). This was true even when other good prognostic factors were present. Eighteen prognostic factors were analyzed, and the effect on survival in each of six age groups was studied. Patients with better performance status, less than three sites of metastases, and without visceral or nodal metastases had a better survival time. A Cox proportional hazards model of survival showed that younger age groups, irrespective of menopausal status, had shorter survival times. The predicted median survival times after the first recurrence were 491 days for patients less than 35 years of age, 590 days for patients 36 to 45 years of age, and 700 days for those greater than 45 years of age.
Assuntos
Neoplasias da Mama/mortalidade , Recidiva Local de Neoplasia/mortalidade , Adulto , Fatores Etários , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Terapia Combinada , Ciclofosfamida/administração & dosagem , Doxorrubicina/administração & dosagem , Feminino , Fluoruracila/administração & dosagem , Humanos , Menopausa , Metotrexato/administração & dosagem , Pessoa de Meia-Idade , Metástase Neoplásica , Recidiva Local de Neoplasia/tratamento farmacológico , Ovariectomia , Prednisona/administração & dosagem , Prognóstico , Fatores de Tempo , Vincristina/administração & dosagemRESUMO
Tamoxifen and trioxifene are antiestrogens that appear to have different endocrine effects when tested in rats. Whereas tamoxifen has considerable clinical activity, trioxifene is a new antiestrogen with undefined clinical activity. Thirty-six patients were treated with graded doses of trioxifene. The low-dose group (0.5 to 12 mg/m2 twice daily) had a 21% response rate in 24 subjects, and the high-dose group (40 to 100 mg/m2 twice daily) had a 33% response rate in 12 patients (P = 0.13). The time to treatment failure was 67 days and 178 days for the low- and high-dose groups, respectively. Toxicities were non-dose dependent; those of moderate frequency included leukopenia (41%) and nausea (31%). Tamoxifen reduced both prolactin and inducible growth hormone (GH). Trioxifene, although reducing prolactin, differed from tamoxifen in that an increase in inducible GH occurred. Furthermore, a striking dose-dependent decrease in luteinizing hormone and lesser decrease in follicle-stimulating hormone occurred only in the trioxifene-treated patients. This implies an intrinsic estrogenic action of trioxifene in man. Trioxifene is no more efficacious than tamoxifen and has more toxicity.
Assuntos
Antineoplásicos/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Glândulas Endócrinas/efeitos dos fármacos , Antagonistas de Estrogênios/uso terapêutico , Pirrolidinas/uso terapêutico , Antineoplásicos/efeitos adversos , Antineoplásicos/farmacologia , Neoplasias da Mama/metabolismo , Relação Dose-Resposta a Droga , Avaliação de Medicamentos , Feminino , Hormônio do Crescimento/metabolismo , Humanos , Prolactina/metabolismo , Pirrolidinas/efeitos adversos , Pirrolidinas/farmacologia , Globulina de Ligação a Hormônio Sexual/análise , Hormônio Liberador de Tireotropina/farmacologiaRESUMO
Elevated levels of platelet-bound IgG (PA-IgG) are a feature of autoimmune thrombocytopenia (ATP), but it is well documented that this does not occur in all cases. This has led us to investigate the role of platelet-bound IgM (PA-IgM) in these patients using a quantitative enzyme-linked immunosorbent assay (ELISA). Forty-five determinations of PA-IgM and PA-IgG were done on 24 patients with ATP. Elevated levels of PA-IgM were found in 93.3% of the determinations, while PA-IgG was elevated in only 71.7%. In 64.4% of determinations, both were elevated. Elevated PA-IgM or PA-IgG alone occurred in 28.9% and 6.7% of determinations, respectively. These results show the hitherto unrecognized frequent involvement of PA-IgM in ATP and suggests that a complex interrelationship exists between the two immunoglobulin classes in ATP. Some of the possibilities that might explain this interrelationship are discussed.
Assuntos
Doenças Autoimunes/sangue , Plaquetas/imunologia , Imunoglobulina M/imunologia , Trombocitopenia/sangue , Ensaio de Imunoadsorção Enzimática , Imunoglobulina G/imunologiaRESUMO
One hundred and sixty-eight patients with unresectable primary liver cancer were prospectively studied by members of the Eastern Cooperative Oncology Group. These patients were randomized to receive treatment with oral 5-Fluorouracil (5FU), oral 5-Fu plus Streptozotocin, oral 5-Fu plus Methyl-CCNU or Adriamycin. The single agent treatments (oral 5-Fu and Adriamycin) were associated with less gastrointestinal toxicity than were the oral 5-Fu treatment combinations. A total of 15 partial responses were reported. Adriamycin appears to be the most active agent and responsible for 9 of the 15 responses. No response was seen in any of the 48 patients randomized to oral 5-Fu alone. The survival associated with oral 5-Fu alone was significantly shorter than the survival time associated with the remaining 3 treatment programs among both North American and South African patients. A multivariate model of survival was formulated. Covariates of prognostic significance were treatment, initial performance status and sex. South African black patients had a shorter survival time than North American black patients. Excluding oral 5-Fu from consideration, prognostic variables appeared to dominate any differences between the remaining treatments under study.
Assuntos
Adenoma de Ducto Biliar/tratamento farmacológico , Antineoplásicos/administração & dosagem , Carcinoma Hepatocelular/tratamento farmacológico , Neoplasias Hepáticas/tratamento farmacológico , Antineoplásicos/efeitos adversos , Medula Óssea/efeitos dos fármacos , Ensaios Clínicos como Assunto , Doxorrubicina/administração & dosagem , Quimioterapia Combinada , Feminino , Fluoruracila/administração & dosagem , Humanos , Masculino , Remissão Espontânea , Semustina/administração & dosagem , Estreptozocina/administração & dosagem , Fatores de Tempo , Vômito/induzido quimicamenteRESUMO
Sera of 184 patients were examined to determine the incidence of hepatitis B surface antigen (HBsAg). Ninety-two patients had primary liver cancer (PLC) and there were 92 matched controls. Thirty-one of the 92 patients with PLC and 8 of the 92 patients with no clinical evidence of liver disease had radio-immunoassay-positive tests for HBsAg. The difference was significant (P less than 0,01). In 56 of the patients with PLC it was possible to assess the nature of associated liver disease histologically. HBsAg was found in the sera of 66,6% of patients with postcollapse cirrhosis and in 22,2% of patients with chronic Budd-Chiari syndrome. It is likely that the role played by hepatitis B infection in the pathogenesis of PLC varies according to local circumstances in different geographical areas.